Release Date: February 18, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: With respect to DTC promotional activities for Auvelity or Symbravo, can you comment on the cadence and strategies for optimizing efficiency? A: Herriot Tabuteau, CEO: We plan to launch a broad-based media outreach for Auvelity in the coming months, ensuring sufficient spend to drive awareness. We will consider calendar year seasonality to optimize media investment. For Symbravo, commercial plans will be shared soon.
Q: Can you provide details on the sales force expansion for Auvelity and its synergy with Symbravo's prescriber base? A: Herriot Tabuteau, CEO: We added about 40 representatives to the Auvelity sales team, a 10-15% increase. There is expected synergy with Symbravo, especially among migraine treaters in primary care, due to overlapping comorbidities with depression.
Q: Will the Alzheimer's disease agitation filing be an NDA or sNDA, and have you had the pre-NDA meeting for AXS-12 for narcolepsy? A: Mark Jacobson, COO: We haven't communicated the filing approach for Alzheimer's yet. For AXS-12, we haven't confirmed the timing for the pre-NDA meeting but will share updates once available.
Q: What are the expectations for the seasonal cadence of scripts and revenues for Auvelity in 2025, especially in Q1? A: Herriot Tabuteau, CEO: We expect Q1 to be a growth quarter, albeit slower than the back half of the year. The sales force expansion is showing positive indicators, and we anticipate incremental growth in new patient starts by the end of Q1.
Q: How are you thinking about M&A and business development given the exclusivity runway for Auvelity and cash generation? A: Nick Pizzie, CFO: We are open to opportunities that complement our pipeline, including earlier-stage assets. We have dedicated resources to evaluate potential opportunities.
Q: Can you provide insights into the PARADIGM study for solriamfetol in MDD and its positioning relative to Auvelity? A: Herriot Tabuteau, CEO: The PARADIGM study is the first with solriamfetol in MDD. If positive, it could be positioned for patients with both excessive daytime sleepiness and depression, leveraging its unique mechanism of action.
Q: How should we think about the launch trajectory and uptake for Symbravo in the migraine market? A: Ari Maizel, CCO: We expect uptake similar to recent oral CGRP launches. Symbravo has a unique clinical profile, and we are targeting headache specialists and neurology practices, which represent 70% of the branded market.
Q: What are the regulatory and commercial considerations for the Alzheimer's disease agitation filing strategy? A: Mark Jacobson, COO: The filing strategy involves considerations across branding, IP, market access, and regulatory aspects. We will provide specific details on our approach soon.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.